Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
Zheng Xian ThngAlbert John BromeoS Saeed MohammadiAnadi KhatriAnh N T TranAmir AkhavanrezayatNgoc T T ThanKhiem S NguyenSeong Jae KimAzadeh MobasserianChristopher Chi Mong OrQuan Dong NguyenPublished in: Expert opinion on emerging drugs (2023)
There has been incredible growth in the number of treatment options available to uveitis patients today, especially with the new generation of biologic drugs. Available evidence suggests that these newer options may be superior to conventional immunosuppressive therapies in terms of efficacy and side effect profiles. Further high-quality research and additional clinical trials will be needed to clarify their roles in the stepladder treatment approach of noninfectious uveitis.
Keyphrases
- clinical trial
- juvenile idiopathic arthritis
- ankylosing spondylitis
- end stage renal disease
- ejection fraction
- rheumatoid arthritis
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- stem cells
- phase ii
- open label
- mesenchymal stem cells
- study protocol
- bone marrow
- patient reported outcomes
- cell therapy
- drug induced